A novel MSC-based immune induction strategy for ABO-incompatible liver transplantation: a phase I/II randomized, open-label, controlled trial

BACKGROUND: ABO-incompatible liver transplantation (ABO-i LT) has become a rescue therapeutic option for patients with severe hepatic failure. Although the use of rituximab greatly reduces the morbidity of antibody-mediated rejection (AMR), severe adverse effects, such as infection and biliary compl...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yingcai, Zhang, Jiebin, Yi, Huimin, Zheng, Jun, Cai, Jianye, Chen, Wenjie, Lu, Tongyu, Chen, Liang, Du, Cong, Liu, Jianrong, Yao, Jia, Zhao, Hui, Wang, Guoying, Fu, Binsheng, Zhang, Tong, Zhang, Jian, Wang, Genshu, Li, Hua, Xiang, Andy Peng, Chen, Guihua, Yi, Shuhong, Zhang, Qi, Yang, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050996/
https://www.ncbi.nlm.nih.gov/pubmed/33863383
http://dx.doi.org/10.1186/s13287-021-02246-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050996/
https://www.ncbi.nlm.nih.gov/pubmed/33863383
http://dx.doi.org/10.1186/s13287-021-02246-4

Ejemplares similares